Zydus Lifesciences Ltd.
ZYDUSLIFEHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
15 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 15 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210820 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211122 | 2021-09-30 | yes | |
| TRANSCRIPT | 20230210 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230524 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230818 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231111 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240214 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240523 | 2024-03-31 | yes | |
| TRANSCRIPT | 20250211 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250527 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250820 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251113 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260215 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260524 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260818 | 2026-06-30 | yes |
ZYDUSLIFE
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,180.30 |
| 52-week range | 860.6 – 1205.0 |
| Return 1M | 4.96% |
| Return 3M | 7.16% |
| Return 1Y | 13.93% |
| Return 3Y | 95.62% |
| Return 5Y | 109.25% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 8,017.00 |
| Other income | 106.00 |
| Total income | 8,123.00 |
| Cost of materials consumed | 1,251.00 |
| Purchases of stock-in-trade | 1,289.00 |
| Changes in inventories | -301.00 |
| Employee benefit expense | 1,368.00 |
| Finance costs | 156.00 |
Ownership — 2026-06-30, and the change from 2026-06-18
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.75 | 0.00 |
| institutions foreign | 0.07 | -0.00 |
| institutions domestic | 0.11 | 0.00 |
| mutual funds | 0.05 | 0.00 |
| public | 0.25 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 15 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 4,135.00 | 4,362.00 | 5,011.00 | 5,140.00 | 4,369.00 | 4,505.00 | 5,534.00 | 6,208.00 | 5,237.00 | 5,269.00 | 6,528.00 | 6,574.00 | 6,123.00 | 6,864.00 | 7,587.00 | 8,017.00 |
| Other income | 44.00 | 38.00 | 38.00 | 36.00 | 54.00 | 38.00 | 156.00 | 63.00 | 68.00 | 58.00 | 81.00 | 155.00 | 109.00 | 111.00 | 134.00 | 106.00 |
| Total income | 4,179.00 | 4,401.00 | 5,048.00 | 5,176.00 | 4,423.00 | 4,543.00 | 5,690.00 | 6,271.00 | 5,305.00 | 5,327.00 | 6,608.00 | 6,729.00 | 6,232.00 | 6,976.00 | 7,721.00 | 8,123.00 |
| Cost of materials consumed | 1,127.00 | 934.00 | 1,210.00 | 1,270.00 | 1,037.00 | 1,063.00 | 1,210.00 | 1,116.00 | 1,066.00 | 1,026.00 | 1,164.00 | 1,219.00 | 1,327.00 | 1,216.00 | 1,347.00 | 1,251.00 |
| Purchases of stock-in-trade | 443.00 | 463.00 | 484.00 | 490.00 | 406.00 | 459.00 | 543.00 | 522.00 | 484.00 | 571.00 | 573.00 | 658.00 | 589.00 | 852.00 | 972.00 | 1,289.00 |
| Changes in inventories | 24.00 | 113.00 | 3.00 | -86.00 | 31.00 | -54.00 | -142.00 | -52.00 | -79.00 | -14.00 | -40.00 | -88.00 | -226.00 | -232.00 | -343.00 | -301.00 |
| Employee benefit expense | 672.00 | 689.00 | 724.00 | 730.00 | 753.00 | 817.00 | 837.00 | 884.00 | 879.00 | 946.00 | 971.00 | 1,005.00 | 1,034.00 | 1,140.00 | 1,239.00 | 1,368.00 |
| Finance costs | 35.00 | 33.00 | 28.00 | 18.00 | 9.00 | 20.00 | 35.00 | 32.00 | 25.00 | 32.00 | 77.00 | 85.00 | 101.00 | 130.00 | 123.00 | 156.00 |
| Depreciation and amortisation | 182.00 | 182.00 | 179.00 | 180.00 | 184.00 | 195.00 | 205.00 | 215.00 | 234.00 | 229.00 | 238.00 | 238.00 | 302.00 | 360.00 | 508.00 | 555.00 |
| Other expenses | 1,053.00 | 1,207.00 | 1,335.00 | 1,230.00 | 996.00 | 1,117.00 | 1,455.00 | 1,654.00 | 1,425.00 | 1,352.00 | 1,734.00 | 1,690.00 | 1,383.00 | 2,072.00 | 1,818.00 | 2,480.00 |
| Total expenses | 3,536.00 | 3,621.00 | 3,961.00 | 3,832.00 | 3,416.00 | 3,617.00 | 4,143.00 | 4,371.00 | 4,034.00 | 4,142.00 | 4,717.00 | 4,808.00 | 4,511.00 | 5,538.00 | 5,664.00 | 6,798.00 |
| Profit before exceptional items and tax | 643.00 | 780.00 | 1,087.00 | 1,343.00 | 1,007.00 | 926.00 | 1,547.00 | 1,900.00 | 1,271.00 | 1,184.00 | 1,892.00 | 1,921.00 | 1,722.00 | 1,438.00 | 2,057.00 | 1,325.00 |
| Exceptional items | 0.00 | 0.00 | -601.00 | -14.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -220.00 | 0.00 | -34.00 | -85.00 | -398.00 | -18.00 |
| Profit before tax | 643.00 | 780.00 | 486.00 | 1,329.00 | 1,007.00 | 926.00 | 1,547.00 | 1,900.00 | 1,271.00 | 1,184.00 | 1,672.00 | 1,921.00 | 1,687.00 | 1,353.00 | 1,660.00 | 1,307.00 |
| Current tax | 186.00 | 129.00 | 230.00 | 625.00 | 253.00 | 150.00 | 465.00 | 654.00 | 366.00 | 39.00 | 991.00 | 231.00 | 379.00 | 244.00 | 526.00 | 376.00 |
| Deferred tax | -49.00 | 66.00 | -93.00 | -409.00 | -27.00 | 64.00 | -144.00 | -218.00 | 8.00 | 140.00 | -567.00 | 203.00 | 75.00 | 144.00 | -207.00 | -22.00 |
| Tax expense | 137.00 | 195.00 | 137.00 | 216.00 | 226.00 | 214.00 | 321.00 | 436.00 | 373.00 | 180.00 | 423.00 | 434.00 | 454.00 | 388.00 | 318.00 | 354.00 |
| Profit for the period | 526.00 | 631.00 | 358.00 | 1,134.00 | 803.00 | 790.00 | 1,246.00 | 1,482.00 | 920.00 | 1,026.00 | 1,244.00 | 1,521.00 | 1,239.00 | 1,023.00 | 1,341.00 | 990.00 |
| Profit attributable to owners | 522.00 | 623.00 | 297.00 | 1,087.00 | 801.00 | 790.00 | 64.00 | 1,420.00 | 911.00 | 1,024.00 | 73.00 | 1,467.00 | 1,259.00 | 1,042.00 | 1,272.00 | 940.00 |
| Profit attributable to non-controlling interests | 4.00 | 8.00 | 62.00 | 47.00 | 2.00 | 0.00 | 1,182.00 | 63.00 | 9.00 | 3.00 | 1,171.00 | 54.00 | -20.00 | -19.00 | 68.00 | 50.00 |
| Other comprehensive income | -87.00 | -75.00 | 5.00 | 6.00 | -56.00 | 20.00 | -170.00 | -24.00 | -10.00 | -43.00 | -23.00 | 5.00 | -274.00 | -22.00 | -483.00 | -32.00 |
| Total comprehensive income | 439.00 | 556.00 | 363.00 | 1,140.00 | 747.00 | 810.00 | 1,076.00 | 1,459.00 | 910.00 | 983.00 | 1,221.00 | 1,526.00 | 964.00 | 1,001.00 | 858.00 | 958.00 |
| Earnings per share, basic | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.35 |
| Earnings per share, diluted | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.35 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 13,166.00 | 14,253.00 | 15,102.00 | 15,265.00 | 17,237.00 | 19,547.00 | 23,242.00 | 27,148.00 |
| Other income | 201.00 | 114.00 | 37.00 | 225.00 | 187.00 | 284.00 | 270.00 | 510.00 |
| Total income | 13,367.00 | 14,367.00 | 15,139.00 | 15,490.00 | 17,424.00 | 19,832.00 | 23,511.00 | 27,658.00 |
| Cost of materials consumed | 2,674.00 | 3,460.00 | 3,888.00 | 4,043.00 | 4,123.00 | 4,580.00 | 4,373.00 | 5,110.00 |
| Purchases of stock-in-trade | 2,152.00 | 1,554.00 | 1,471.00 | 1,865.00 | 1,949.00 | 1,898.00 | 2,150.00 | 3,070.00 |
| Changes in inventories | -110.00 | -94.00 | -149.00 | -362.00 | 238.00 | -250.00 | -185.00 | -888.00 |
| Employee benefit expense | 2,124.00 | 2,414.00 | 2,490.00 | 2,434.00 | 2,766.00 | 3,138.00 | 3,681.00 | 4,418.00 |
| Finance costs | 194.00 | 342.00 | 164.00 | 127.00 | 130.00 | 81.00 | 166.00 | 439.00 |
| Depreciation and amortisation | 599.00 | 696.00 | 725.00 | 713.00 | 723.00 | 764.00 | 916.00 | 1,408.00 |
| Other expenses | 3,352.00 | 4,135.00 | 4,061.00 | 3,945.00 | 4,302.00 | 4,797.00 | 6,164.00 | 6,963.00 |
| Total expenses | 10,985.00 | 12,508.00 | 12,650.00 | 12,764.00 | 14,230.00 | 15,008.00 | 17,265.00 | 20,520.00 |
| Profit before exceptional items and tax | 2,382.00 | 1,859.00 | 2,490.00 | 2,725.00 | 3,194.00 | 4,823.00 | 6,246.00 | 7,138.00 |
| Exceptional items | 0.00 | -364.00 | -205.00 | 113.00 | -604.00 | -14.00 | -220.00 | -517.00 |
| Profit before tax | 2,382.00 | 1,495.00 | 2,285.00 | 2,838.00 | 2,590.00 | 4,809.00 | 6,027.00 | 6,621.00 |
| Current tax | 607.00 | 238.00 | 466.00 | 442.00 | 690.00 | 1,493.00 | 2,049.00 | 1,380.00 |
| Deferred tax | -77.00 | 82.00 | -318.00 | 70.00 | -103.00 | -515.00 | -637.00 | 215.00 |
| Tax expense | 530.00 | 320.00 | 147.00 | 512.00 | 588.00 | 978.00 | 1,412.00 | 1,595.00 |
| Profit for the period | 1,899.00 | 1,204.00 | 2,185.00 | 4,618.00 | 2,092.00 | 3,973.00 | 4,673.00 | 5,124.00 |
| Profit attributable to owners | 1,849.00 | 1,177.00 | 2,134.00 | 4,487.00 | 1,960.00 | 113.00 | 147.00 | 5,040.00 |
| Profit attributable to non-controlling interests | 50.00 | 28.00 | 51.00 | 131.00 | 132.00 | 3,860.00 | 4,526.00 | 84.00 |
| Other comprehensive income | -168.00 | -300.00 | 73.00 | -104.00 | -314.00 | -200.00 | -100.00 | -775.00 |
| Total comprehensive income | 1,731.00 | 904.00 | 2,258.00 | 4,514.00 | 1,778.00 | 3,773.00 | 4,573.00 | 4,349.00 |
| Earnings per share, basic | 18.06 | 11.49 | 20.84 | 43.84 | 19.30 | 38.14 | 44.97 | 50.09 |
| Earnings per share, diluted | 18.06 | 11.49 | 20.84 | 43.84 | 19.30 | 38.14 | 44.97 | 50.09 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 25,629.00 | 25,756.00 | 25,879.00 | 29,281.00 | 31,446.00 | 37,202.00 | 46,897.00 | 52,407.00 |
| Non-current assets | 15,918.00 | 15,740.00 | 15,945.00 | 17,779.00 | 19,289.00 | 20,156.00 | 28,584.00 | 32,500.00 |
| Current assets | 9,667.00 | 10,008.00 | 9,928.00 | 11,420.00 | 12,119.00 | 17,046.00 | 18,313.00 | 19,906.00 |
| Property, plant and equipment | 5,764.00 | 5,696.00 | 5,717.00 | 5,803.00 | 6,102.00 | 6,042.00 | 7,099.00 | 9,231.00 |
| Capital work-in-progress | 958.00 | 1,130.00 | 1,220.00 | 1,112.00 | 1,051.00 | 1,318.00 | 1,190.00 | 1,166.00 |
| Goodwill | 5,406.00 | 4,804.00 | 4,804.00 | 5,266.00 | 5,266.00 | 5,242.00 | 7,755.00 | 7,543.00 |
| Other intangible assets | 1,101.00 | 1,020.00 | 983.00 | 1,299.00 | 1,617.00 | 1,850.00 | 5,495.00 | 7,332.00 |
| Inventories | 3,405.00 | 3,413.00 | 3,304.00 | 3,442.00 | 3,717.00 | 3,944.00 | 4,750.00 | 5,628.00 |
| Trade receivables | 3,725.00 | 4,417.00 | 3,915.00 | 5,220.00 | 4,670.00 | 4,025.00 | 4,963.00 | 5,416.00 |
| Cash and cash equivalents | 455.00 | 488.00 | 346.00 | 413.00 | 1,061.00 | 827.00 | 882.00 | 855.00 |
| Total equity and liabilities | 25,629.00 | 25,756.00 | 25,879.00 | 29,281.00 | 31,446.00 | 37,202.00 | 46,897.00 | 52,407.00 |
| Equity | 18,768.00 | 19,688.00 | 20,941.00 | 22,102.00 | 24,155.00 | 26,358.00 | 28,090.00 | 29,582.00 |
| Equity share capital | 101.00 | 101.00 | 101.00 | 101.00 | 101.00 | 101.00 | 101.00 | 101.00 |
| Other equity | 16,564.00 | 17,415.00 | 18,632.00 | 19,729.00 | 21,724.00 | 23,852.00 | 25,201.00 | 27,011.00 |
| Total liabilities | 6,862.00 | 6,068.00 | 4,938.00 | 7,179.00 | 7,291.00 | 10,843.00 | 18,807.00 | 22,824.00 |
| Non-current liabilities | 741.00 | 537.00 | 576.00 | 1,837.00 | 1,940.00 | 1,802.00 | 9,360.00 | 7,112.00 |
| Current liabilities | 6,114.00 | 5,527.00 | 4,358.00 | 5,340.00 | 5,349.00 | 9,042.00 | 9,448.00 | 15,712.00 |
| Borrowings, non-current | 288.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6,779.00 | 3,188.00 |
| Borrowings, current | 2,130.00 | 1,163.00 | 150.00 | 769.00 | 150.00 | 3,170.00 | 2,815.00 | 8,582.00 |
| Trade payables | 1,802.00 | 2,125.00 | 1,636.00 | 2,127.00 | 2,127.00 | 2,306.00 | 2,462.00 | 2,845.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 1,129.00 | 2,689.00 | 2,213.00 | 3,228.00 | 3,579.00 | 6,777.00 | 946.00 | 2,117.00 |
| Net cash from investing activities | -540.00 | 1,171.00 | -709.00 | -1,475.00 | -1,982.00 | -8,372.00 | -5,193.00 | -8,296.00 |
| Net cash from financing activities | -3,064.00 | -4,400.00 | -1,645.00 | -1,804.00 | -931.00 | 2,031.00 | 4,223.00 | 5,997.00 |
| Purchase of property, plant and equipment | 531.00 | 1,031.00 | 465.00 | 907.00 | 974.00 | 1,713.00 | 868.00 | 3,394.00 |
| Net increase in cash | -2,476.00 | -534.00 | -142.00 | -75.00 | 648.00 | 414.00 | 55.00 | 28.00 |
| con:CFO.BEFORE_TAX | 1,343.00 | 3,281.00 | 2,776.00 | 4,514.00 | 4,334.00 | 8,579.00 | 1,971.00 | 3,708.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 209.00 | 592.00 | 563.00 | 1,286.00 | 755.00 | 1,802.00 | 1,025.00 | 1,591.00 |
| con:CF_OTHER.OPERATING | -5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 10.00 | 0.00 | 106.00 | 107.00 | 39.00 | 42.00 | 14.00 | 345.00 |
| con:INVESTMENTS_SOLD | 35.00 | 40.00 | 0.00 | 55.00 | 10.00 | 216.00 | 0.00 | 112.00 |
| con:PPE_DISPOSALS | 0.00 | 39.00 | 20.00 | 24.00 | 45.00 | 51.00 | 9.00 | 25.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 720.00 | 650.00 | 369.00 | 5,464.00 | 5,879.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 18.00 | 18.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 671.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-18 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.99 | 74.99 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 |
| Domestic institutions | 13.52 | 13.09 | 13.03 | 12.63 | 12.64 | 10.65 | 10.65 | 11.01 | 11.13 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Mutual funds | — | — | — | — | — | — | — | — | 5.56 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Insurance companies | 7.43 | 6.86 | 5.80 | 5.74 | 5.22 | 3.85 | 4.08 | 4.38 | 5.29 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
| Foreign institutions | 4.04 | 4.86 | 5.00 | 5.72 | 5.59 | 7.52 | 7.53 | 7.32 | 7.13 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Government | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 25.02 | 25.02 | 25.02 | 25.02 | 25.02 | 25.02 | 25.02 | 25.01 | 25.01 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Non-institutional | 7.47 | 7.07 | 6.99 | 6.66 | 6.80 | 6.85 | 6.84 | 6.68 | 6.74 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Shares outstanding | 1012204139 | 1012204139 | 1012204139 | 1006233990 | 1006233990 | 1006233990 | 1006233990 | 1006233990 | 1006233990 | 1006233990 | 1006233990 | 1006233990 | 997503832 | 997503832 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Zydus Pharmaceuticals (USA) Inc. | Subsidiary Company | Any other transaction, Interest received, Loan, Sale | 50,037,240,000.00 | 18 |
| Zydus Animal Health and Investments Limited | Subsidiary Company | Any other transaction, Interest paid, Investment, Lo | 14,934,070,000.00 | 11 |
| Sentynl Therapeutics Inc. | Subsidiary Company | Any other transaction, Interest received, Loan, Sale | 13,210,430,000.00 | 10 |
| Zydus Lifesciences Global FZE [UAE] | Subsidiary Company | Any other transaction, Interest received, Investment | 9,353,500,000.00 | 13 |
| Sterling Biotech Limited | Joint Ventures | Any other transaction, Investment, Purchase of goods | 6,508,780,000.00 | 3 |
| Zydus Wellness Products Limited | Subsidiary Company | Any other transaction, Interest received, Loan, Purc | 4,004,390,000.00 | 20 |
| Zydus Lifesciences Limited | Parent Company | Any other transaction, Loan, Sale of fixed assets | 3,728,560,000.00 | 5 |
| Zydus Healthcare Limited | Subsidiary Company | Any other transaction, Interest paid, Loan, Purchase | 3,266,710,000.00 | 16 |
| Viona Pharmaceuticals INC | Subsidiary Company | Any other transaction, Interest received, Investment | 2,013,350,000.00 | 16 |
| Zydus Therapeutics INC | Subsidiary Company | Any other transaction, Interest received, Loan, Sale | 1,805,730,000.00 | 10 |
| Zydus Worldwide DMCC | Subsidiary Company | Any other transaction, Interest received, Loan, Sale | 1,596,450,000.00 | 10 |
| ZyVet Animal Health Inc | Subsidiary Company | Any other transaction, Interest received, Loan, Sale | 1,375,680,000.00 | 9 |
| Zydus Pharmaceuticals Limited | Subsidiary Company | Any other transaction, Investment, Purchase of goods | 1,205,430,000.00 | 7 |
| Zydus Medtech Private Limited | Subsidiary Company | Any other transaction, Interest received, Investment | 892,890,000.00 | 7 |
| Zydus Healthcare S.A. (Pty) Ltd | Subsidiary Company | Any other transaction, Interest received, Purchase o | 735,140,000.00 | 10 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-18 | Q1FY27 | Read the call | |
| 2026-05-24 | Q4FY26 | Read the call | |
| 2026-02-15 | Q3FY26 | Read the call | |
| 2025-11-13 | Q2FY26 | Read the call | |
| 2025-08-20 | Q1FY26 | LIFESCIENCES LIMITED | Read the call |
| 2025-05-27 | Q4FY25 | Read the call | |
| 2025-02-11 | Q3FY25 | Read the call | |
| 2024-05-23 | Q4FY24 | Read the call | |
| 2024-02-14 | Q3FY24 | Read the call | |
| 2023-11-11 | Q2FY24 | Read the call | |
| 2023-08-18 | Q1FY24 | Read the call | |
| 2023-05-24 | Q4FY23 | Read the call | |
| 2023-02-10 | Q3FY23 | Read the call | |
| 2021-11-22 | Q2FY22 | CADILA HEALTHCARE LTD, HEALTHCARE LTD | Read the call |
| 2021-08-20 | Q1FY22 | CORPORATE FINANCE, CADILA HEALTHCARE, EXECUTIVE DIRECTOR, CADILA HEALTHCARE, HEALTHCARE LI | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | My final question is your capex is currently trending at around 10 billion for a year so, where are the major spend happening? | — | So, there is going to be a higher cycle of capex at least for this coming year and maybe one more. | — | — | — | — | So, we are thinking, in FY27, around 1,500 crore capex number. |
| Capital allocation | — | My second question is on the LiqMed acquisition that we announced last quarter. | So, non-recurring because of some specific legal and professional assignment related to some acquisition that we have done and GST loss on inventory d… | The acquisition of Comfort Click has uniquely positioned us with a strong presence in both India and Europe's developed markets, enhancing diversifica… | So right now, whatever I see on consol balance sheet is more or less Heinz acquisition? | In the specialty space, acquisition of LiqMeds has augmented our capabilities to deliver novel solutions to the patients while in the rare disease spa… | Is there any update on speciality acquisition in the orphan drug space in the US, especially for the launch of Saroglitazar approaching? | We are accelerating our US specialty oncology strategy through the proposed acquisition of Assertio holdings. |
| Costs | Yeah, but in the cost front also there isn't, there isn't no saving, right? | — | — | — | A quick question on Vascepa, your thoughts about when do you plan to launch, are there any raw material availability issues and the market dynamics? | — | — | And lastly, on the current geopolitical environment and its impact on the supply chain, what kind of disruption are we witnessing from, let's say, fue… |
| Debt and cash | So, first question is on the working capital side, over the last nine months looks like it has gone up much more than the sales growth. | — | — | As I said, our internal accruals are, I mean, and cash flows are sufficient for us to continue to do what we need to do without fund raise. | — | — | — | Just one on the debt side, we are already at more around 4,500 crore debt, and with the buyback and Assertio acquisition, we would be almost close to … |
| Demand | We are confident of sustaining the growth momentum across our key markets led by strong product pipeline and focused execution efforts. | In the consumer wellness space, our category leading brands like Glucon D, Everyuth Scrub & Peel Off and Nycil gained market share during the quarter … | So, we have a pipeline that we believe is quite robust on the conservative side. | Excluding the impact of the recently acquired Comfort Click, the business delivered double-digit volume growth during the quarter, reflecting the unde… | A couple of questions around the US pipeline. | On the Consumer Wellness front, the FMCG sector witnessed gradual improvement in demand during the quarter with an uptick in demand also in rural Indi… | While I stated that our base business has continued to grow, so we are also quite excited that our products that we currently also sell, are seeing a … | Our international markets business, spanning emerging markets and Europe, sustained strong momentum with demand-led growth across geographies. |
| Guidance | Could this trend up further, I know this is within our guidance range of 7 to 8 % but on an absolute basis how much could it trend up further as we ma… | On the NCE research front, during the quarter, we expect to complete the patient recruitment for our phase II(b)/III clinical trials of Saroglitazar M… | But I think it's a very, I would say it's a good acquisition that we have done and it's doing better than what we expected. | Yeah, so our current run rate in terms of other expenses, excluding R&D expenditure for this particular quarter, and what we expect is about ₹1,750-₹1… | As I say, on the overall guidance that I said, what we're trying to do is maintain and protect our base. | We could improve our profitability in the range of 50-70 basis points in the past on account of such initiatives and we expect similar improvement goi… | So, let’s say what you guided last time was what you guiding now. | We expect the business to deliver steady performance in the coming quarters. |
| Margin | EBITDA margin for the quarter stood at 21.9%, which is an improvement of 130 basis points on a year-on-year and 220 basis points on a quarter- on-quar… | EBITDA margin for the quarter stood at 24.5% which is an improvement of 200 basis points on a year on year basis. | So, are you doing any adjustment to that and hence your margin as it is reported in the presentation is different than what we do find? | Excluding acquisitions too, the base sustained double-digit growth with all key businesses delivering ahead of expectations. • EBITDA for the quarter … | So, anything to read out there and what is the margin like, we could see better margin going forward or this with 8% R&D, 22 is a good margin to model… | The business delivered robust operating performance with an EBITDA margin of 27.5%, which is an improvement of 510 basis points over the previous year… | Any colour that you can provide as to you know, that uptick and how sustainable that gross margin will be if we think about next year? | A strong product mix combined with operating leverage and forex tailwinds propelled profitability. |
| People | — | — | — | No, I think, as I said, it will slowly ramp up because it depends once on filing and how we are going ahead with the hiring and other strategic initia… | — | — | — | We shall maximize the utilization of these facilities through continued BOT-BAL supply to Agenus and onboarding of new partners. |
| Pricing | However, we have taken appropriate price increases to counter this, the impact of which will be reflected from the next quarter. | — | And you know, given this is a rare disease asset, you know, how should we think about pricing? | — | And when we look at pricing scenario in US, like not just for our portfolio, but overall industry, how do you see the US pricing today? | So, the product mix, the wellness business seeing the inflationary pressures ease and better pricing realization and obviously the mix of markets that… | So, wellness, we have been able to take some price increase also. | And also the pricing growth in both the years is also very strong. |
| Revenue growth | Excluding revenues from COVID related products and divested brands during Q3 and for the first nine months of the current fiscal, the business deliver… | For the first nine months of the current fiscal, the growth was 15%, driven by healthy double- digit growth registered in all our key markets. | On a YTD basis, we have grown at 9% with this quarter growth of 5% and which is better than market. | The growth was driven by persistent traction in innovation products and the pillar brands. | See, it's difficult to, I think that'd be difficult to say I mean, whether we are in, it's obviously not going to, it will be, we hope it’s double dig… | — | — | Chronic segment continued to grow at a faster pace, driving the overall growth of the business. |